Quantcast
Home > Quotes > SGEN
SGEN

Seattle Genetics, Inc. Common Stock (SGEN) Quote & Summary Data

$70.64
*  
1.10
1.53%
Get SGEN Alerts
*Delayed - data as of Jun. 24, 2019  -  Find a broker to begin trading SGEN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
80
Today's High / Low
$ 72.20 / $ 70.11
Share Volume
606,080
50 Day Avg. Daily Volume
729,828
Previous Close
$ 71.74
52 Week High / Low
$ 84.37 / $ 50.71
Market Cap
11,395,264,969
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.78
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.91

Intraday Chart

Shares Traded

Share Volume:
606,080
50 Day Avg. Daily Volume:
729,828

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.78

Trading Range

The current last sale of $70.64 is 39.30% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 72.20 $ 84.37
 Low: $ 70.11 $ 50.71

ETFs with SGEN as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
3.04% Principal Healthcare Innovators Index ETF (BTEC) +1.60 (5.00%)
0.2% Fidelity MSCI Health Care Index ETF (FHLC) +2.76 (6.48%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

Seattle Genetics is a biotechnology company that develops and commercializes therapies targeting cancer. We are commercializing ADCETRIS┬«, or brentuximab vedotin, for the treatment of several types of lymphoma. We are also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Many of our programs, including ADCETRIS, are based on our antibody-drug conjugate, or ADC, technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Our marketed product ADCETRIS is commercially available in 72 countries, including in the U.S., Canada, members of the European Union and Japan. We commercialize ADCETRIS in the U.S. and its territories and in Canada, and we are collaborating with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS on a global basis.  ... More ...  



Risk Grade

Where does SGEN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 72.20
Open Date:
Jun. 24, 2019
Close Price:
$ 70.64
Close Date:
Jun. 24, 2019


Consensus Recommendation

Analyst Info